Deuterium Metabolic Imaging to Assess Radiotherapy Changes in Glioblastoma Multiforme

Condition(s) studied

Investigational drug(s) / intervention(s)

Deuterium metabolic imaging: MRI after oral administration of 75g of \[6,6'-2H2\]glucose.

Study summary

This is a feasibility single arm study designed for obtaining early data for optimization and evaluation of the clinical potential for a new MR technique using deuterated glucose. The purpose of the study is to investigate whether this technique is useful in metabolic imaging of glioblastoma multiforme (GBM) and whether radiochemotherapy (RCT) induced changes in the brain metabolism can be detected and might be predictive for treatment response. The study will include 10 patients with histologically verified GBM scheduled for standard RCT. Patients will have MRI scan performed before and within 8 weeks after starting RCT. The scans will include imaging after oral intake of deuterated glucose, so called deuterium metabolic imaging (DMI). Based on this study, the most optimal scanning technique, output variables of highest discriminative power with respect to RCT, and potential predictive markers for response will be selected for further clinical investigation.

Eligibility

Primary outcome measure(s)

• Deuterium Metabolic Imaging — Imaging repeated twice with ~10 weeks between them.
  2H-glucose uptake and conversion to lactate and glx over 120 minutes in normal brain and tumor tissue. Before and after radiochemotherapy to measure the changes with therapy.

Trial sites (1)

More University of Aarhus trials in Denmark